Use of PDE5 inhibitors in the treatment of scarring
AssigneePfizer Inc.
InventorsRichard Philip Butt, Stephen Charles Phillips
Life of this patent
Estimating the term…
Abstract
This invention relates to the use of selective cyclic guanosine 3′,5′-monophosphate type five (cGMP PDE5) inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of or prevention of scarring or fibrosis in tissue.
Claims13
A method for reducing scarring and/or treating fibrosis in a patient which comprises treating the patient with an effective amount of a cGMP PDE5 inhibitor, or a pharmaceutical composition thereof.
The use of a cGMP PDE5 inhibitor for the manufacture of a medicament for reducing scarring and/or treating fibrosis.
A method or use as claimed in any preceding claim, wherein the wherein the inhibitor has an IC50 at less than 100 nanomolar.
A method or use as claimed in any preceding claim, wherein the inhibitor is sildenafil.
The use of a cGMP PDE5 inhibitor in combination with a PCP and/or PDE4 inhibitor for the manufacture of a medicament for reducing scarring and/or treating fibrosis.
A pharmaceutical pack comprising:
- a pharmaceutical composition comprising a PDE5 inhibitor, directions relating to the use of the composition for reducing scarring and/or treating fibrosis, and a container.
A combination of a PDE5 inhibitor together with a PCP inhibitor and/or a PDE4 inhibitor (uPA).
Dependencies are inferred from the claim text.